Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance.

PURPOSE: To identify molecular factors that determine duration of response to EGFR tyrosine kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly profiled EGFR mutant tumors prior to treatment and after progression on EGFR TKI using targeted next-generation sequencing...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Yu, Helena A., Suzawa, Ken, Jordan, Emmet, Zehir, Ahmet, Ni, Ai, Kim, Ryan, Kris, Mark G., Hellmann, Matthew D., Li, Bob T., Somwar, Romel, Solit, David B., Berger, Michael F., Arcila, Maria, Riely, Gregory J., Ladanyi, Marc
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6420806/
https://ncbi.nlm.nih.gov/pubmed/29530932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2961
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados